Comparison of Nusinersen Monotherapy Versus Combination Therapy With Nusinersen and Onasemnogene Abeparvovec in Spinal Muscular Atrophy Type 1 Patients With Two SMN2 Copies: A Multicenter Study From Türkiye
Muscle & Nerve · 2026-06 · 73 (6) · 966-975
DOI: 10.1002/mus.70191 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Muscle & Nerve, online erschienen am 27.02.2026. Verfasst von Hulya Maras Genc und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Neurology, Department of Pediatrics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye. Hauptthemen laut MEDLINE: Spinal Muscular Atrophies of Childhood, Oligonucleotides, Survival of Motor Neuron 2 Protein, Recombinant Fusion Proteins. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Introduction/Aims Data comparing nusinersen monotherapy with combination therapy using nusinersen and onasemnogene abeparvovec (OA) in spinal muscular atrophy (SMA) type 1 patients are limited. This study aimed to compare the clinical outcomes of nusinersen monotherapy versus combination therapy (nusinersen and OA) in SMA type 1 patients with two SMN2 copies.
Methods
This retrospective multicenter study included 82 patients divided into nusinersen monotherapy ( n = 42) and combination therapy ( n = 40) groups. Outcomes included motor milestones, Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP‐INTEND) scores, respiratory and nutritional status, and survival. Patients were stratified by age at treatment initiation (≤ 3, 3–6, and > 6 months). An age‐matched subgroup analysis was performed.
Results
Age at treatment initiation, total administered nusinersen doses, and follow‐up duration were comparable between groups. All deaths ( n = 8) occurred in the monotherapy group among patients who initiated treatment after 3 months of age ( p = 0.005). There was no significant difference between groups in the age at achieving unsupported sitting. In the age‐matched subgroup analysis ( n = 44, 22 per group), no significant differences were found between monotherapy and combination therapy in terms of motor function, CHOP‐INTEND progression, respiratory and feeding status. Earlier treatment was associated with better feeding outcomes (OR: 0.740, p = 0.024). Pre‐treatment respiratory and feeding status were also predictive of corresponding outcomes.
Discussion
Early treatment is the main determinant of outcomes, while combination therapy shows no clear advantage over monotherapy. Larger prospective studies are needed to clarify the role and timing of combination therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Neurology, Department of Pediatrics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
- Division of Pediatric Neurology, Department of Pediatrics, Sanliurfa Training and Research Hospital, Sanliurfa, Türkiye.
- Division of Pediatric Neurology, Department of Pediatrics, Marmara University School of Medicine, Istanbul, Türkiye.
- Division of Pediatric Neurology, Department of Pediatrics, Kocaeli University Faculty of Medicine, Istanbul, Türkiye.
- Division of Pediatric Neurology, Department of Pediatrics, Istanbul University-Cerrahpaşa Cerrahpaşa Faculty of Medicine, Istanbul, Türkiye.
- Division of Pediatric Neurology, Department of Pediatrics, Mersin University Faculty of Medicine, Istanbul, Türkiye.
ORCID-Profile: Ayfer Sakarya Gunes, Mehmet Akif Kilic
Zitieren
APA
Genc, H. M., Kurekci, F., Ozturk, G., Gunes, A. S., Saltik, S., Kilic, M. A., Cirdi, G., Unver, O., Komur, M., Akbeyaz, I. H., Zindar, Y., Orgun, L. T., Kayar, C. D., Guler, S., Caglar, E., Sengec, E., Yildiz, E. P., Kara, B., Turkdogan, D., & Marmara Region SMA Study Group (2026). Comparison of Nusinersen Monotherapy Versus Combination Therapy With Nusinersen and Onasemnogene Abeparvovec in Spinal Muscular Atrophy Type 1 Patients With Two SMN2 Copies: A Multicenter Study From Türkiye. Muscle & Nerve, 73(6), 966-975. https://doi.org/10.1002/mus.70191
Vancouver
Genc HM, Kurekci F, Ozturk G, Gunes AS, Saltik S, Kilic MA, et al. Comparison of Nusinersen Monotherapy Versus Combination Therapy With Nusinersen and Onasemnogene Abeparvovec in Spinal Muscular Atrophy Type 1 Patients With Two SMN2 Copies: A Multicenter Study From Türkiye. Muscle & Nerve. 2026;73(6):966-975. doi:10.1002/mus.70191
BibTeX
@article{Genc2026,
author = {Genc, Hulya Maras and Kurekci, Fulya and Ozturk, Gulten and Gunes, Ayfer Sakarya and Saltik, Sema and Kilic, Mehmet Akif and Cirdi, Gokce and Unver, Olcay and Komur, Mustafa and Akbeyaz, Ismail Hakki and Zindar, Yılmaz and Orgun, Leman Tekin and Kayar, Cisem Duman and Guler, Serhat and Caglar, Ezgi and Sengec, Esma and Yildiz, Edibe Pembegul and Kara, Bulent and Turkdogan, Dilsad and Marmara Region SMA Study Group, Marmara Region SMA Study Group},
title = {Comparison of Nusinersen Monotherapy Versus Combination Therapy With Nusinersen and Onasemnogene Abeparvovec in Spinal Muscular Atrophy Type 1 Patients With Two SMN2 Copies: A Multicenter Study From Türkiye},
journal = {Muscle & Nerve},
year = {2026},
volume = {73},
number = {6},
pages = {966--975},
doi = {10.1002/mus.70191}
}
EUVIMED